Clinical Trial Update: Safety, Tolerability and Pharmacokinetics of SH-1028 in Patients With Advanced NSCLC [Phase 1]

View source ↗

Summary

This Phase 1 trial update reports on the safety, tolerability, and pharmacokinetics of SH-1028 in patients with advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• SH-1028 (SH-1028)

Snippet

Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 1 | Status: UNKNOWN